April 21st 2025
Treatment with nadofaragene led to a complete response rate of 75% at 3 months.
Impact of cisplatin ineligibility on receiving adjuvant therapy for UTUC
February 15th 2022Shawn Dason, MD, discusses the findings and takeaways of the study, "How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?"
Study demonstrates feasibility of antegrade instillation of Jelmyto for UTUC
February 11th 2022“While Jelmyto is approved for both retrograde and antegrade instillation, the instructions for administration address retrograde instillation, and this is the first time that data on antegrade instillation has been documented in a clinical setting for this chemoablative therapy,” said Katie Murray, DO.
Gender disparities found in bladder cancer trials and real-world systemic therapy use
February 8th 2022“We have to be more mindful and thoughtful about the fact that certain populations are underrepresented in clinical trials, and that’s likely due to a number of factors,” said co-author Padraic O’Malley, MD, MSc, FRCSC.
Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists
January 24th 2022“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.
Dr. Bupathi discusses JAVELIN Bladder 100 trial of maintenance avelumab
January 13th 2022In the study, adding maintenance avelumab to best supportive care (BSC) led to a 31% reduction in the risk of death versus BSC alone in patients with unresectable locally advanced or metastatic urothelial cancer.
The current state of organ-sparing radical cystectomy for women
January 3rd 2022As an advocate for patients, Svetlana Avulova, MD, stresses the importance of this population of women with bladder cancer and how their desire to preserve sexual function through organ-sparing treatment should be recognized and validated.